2007 Drug Trend Brian Seiz, PharmD Express Scripts.

Slides:



Advertisements
Similar presentations
Commonwealth Connector Minimum Pharmacy Standards October 11, 2007.
Advertisements

Confidential and Proprietary Information © 2011 Express Scripts, Inc. All Rights Reserved 1 The State of New Mexico Prescription Drug Program 2013.
Pharmacy Costs: “Can I Make a Difference?” September, 2014.
Third Quarter 2002 October 25, 2002 Note to Internet viewers: Please use “NOTES PAGES” view to access all notes and text.
Solution in Drug Plan Management 2011 September 8, 2011 Basil Rowe Vice President, Total Rewards and Shared Services Shoppers Drug Mart
Torrent Pharmaceuticals Ltd Investor Presentation FY 2011.
Utah All Payer Database (APD) Introduction to the Reporting Capabilities of the Utah All Payer Database Mark Gaskill, MFT Keely Cofrin.
Indiana University School of Medicine Department of Psychiatry Psychiatry Resident and Psychology Intern Training Program Update August 19, 2008 Christopher.
Preparing for What’s on the Prescription Drug Benefit Horizon Brenda Motheral, PhD Senior Vice President Research & Product Management.
Trends in Electric Rates in the Midwest by Charlie Higley Citizens Utility Board of Wisconsin for Energy Utility Basics Wisconsin Public Utility Institute.
A Prescription for Success …expanding your PBM know-how 2009 Retiree Symposium Making the Prescription Drug Benefit Work for You Presented by: Ashley Blevins.
Innovations: Using a Clinical Pharmacist as a Vehicle for Successful P4P Outcomes Lisa Meland, B.S., PharmD. Helen Pervanas, R.Ph. WellPoint-WellPoint.
Anesthetic and Life Support Drugs, and Drug Safety and Risk Management Advisory Committees, November 13, 2008 Outpatient Drug Utilization Trends for Oxycodone.
Dallas ISCEBS The Hidden Issues Behind Increasing Pharmacy Costs April 10, Metro Blvd, Suite 210, Edina MN |
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
 2003 Express Scripts, Inc. All Rights Reserved The Medicare Prescription Drug Benefit and PBMs Barrett Toan Chief Executive Officer Express Scripts,
Specialty Pharmacy: Today’s Prescription for a Better Tomorrow Steve Miller, MD Chief Medical Officer.
1 Generic Substitution in Medicare Part D Plans Jack Hoadley, Georgetown University Katie Merrell, Social & Scientific Systems Elizabeth Hargrave, NORC.
URx : Rethinking our Rx program: A New Strategic Approach.
ABLE LABORATORIES, INC.. Safe Harbor Statement Except for historical facts, the statements in this presentation, as well as oral statements or other written.
How GMs, Boards and CFOs Utilize the KRTA CDPAA March 2015 Meeting Ty Harrell, CFC RVP for MS and TN 3/19/15.
Chapter 2 Situation & Environmental Analysis. COPYRIGHT © 2002 Thomson Learning, Inc. All rights reserved. Components of a Situation Analysis... Internal.
U.S. Drug Costs Dropped in 2012, but Rises Loom Katie Thomas The New York Times March 18, 2013
UMSYSTEM.EDU November 19, UMSYSTEM.EDU Missouri S&T Faculty Senate November 19, 2009.
Prescription Drug Trends Sean Keehan, Senior Economist Office of the Actuary Centers for Medicare and Medicaid Services Middle Atlantic Actuarial Club.
Inside the Black Box: How Actuaries Price Health Insurance Academy Health Annual Research Meeting June 8 th 2004 Lisa F. Tourville, ASA, MAAA Vice President.
EPC EDUCATION AND TRAINING – Applications for Membership of the EU Turkey - April 1987 Cyprus - July 1990 Malta - July 1990 Hungary.
Nathan Mendes Ronnie Ng Scott Perkins Zvi Rhine Zack Weaver Symbol: MRK Exchange: NYSE 12/4/2000.
Lehman Brothers 9th Annual Global Healthcare Conference March 8, 2006.
2006 Drug Trend Julayna Meyer, R.Ph, MBA Vice President Trend Management.
Pharmacoeconomic Center Conference January 8, 2007 RADM Tom McGinnis, U.S.P.H.S. Chief, DoD Pharmaceutical Operations Directorate V5.
Merck & Co., Inc. Recommendation Sell Yuqian(Annie) Zhang Nov. 4 th, 2004.
Title text here Consumer Perspective on Containing Drug Costs Leigh Purvis, Director, Health Services Research.
Food Bites Confectionery Bars Snacks and Confectionery Annual Market Quantification March 2011.
Actuarial Overview of Premium Rate Development Presented by Susan E. Pantely, FSA, MAAA Milliman, Inc. San Francisco, CA
4th Annual Investor Conference May 16, 2001 HEALTH PLANS DIVISION Cora Tellez President.
Consumer-Driven Health Plans: Early Cost & Use Evidence with a Focus on Pharmaceuticals Stephen T Parente Jon B Christianson Roger Feldman August, 2004.
The essence of global pharmaceutical marketing. Definitions of marketing ‘Marketing is the management process that identifies, anticipates and satisfies.
Strictly confidential How to achieve sustainability in rapidly changing environment? Pavle Marjanović, Country Manager for Actavis Republic of Serbia and.
August 4, 2009 ORANGE COUNTY 2010 MEDICAL PLAN CHANGES.
Walgreens Health Initiatives Maximizing Your Rx Drug Benefits Presented to Drury University Michele Pence Account Manager.
Can the Specialty Beast Be Tamed? Steven B. Miller, MD Express Scripts.
Confidential and Proprietary Information © 2014 Express Scripts Holding Company. All Rights Reserved. 1 Confidential and Proprietary Information © 2014.
Growth in prescription spending had slowed, but increased rapidly in 2014 and 2015 Average annual growth rate of prescription drug spending per capita.
The Cost of Reference-Priced Generic Drug Coverage.
1 May 2008 Macroview Event Report: Abbott’s Humira to become industry’s leading product in 2014 TITLE: Abbott’s Humira to become industry’s leading brand.
Source: Kaiser Family Foundation analysis of National Health Expenditure (NHE) Historical ( ) data from Centers for Medicare and Medicaid Services,
1 PROPRIETARY AND CONFIDENTIAL © 2013 Express Scripts Holding Company. All Rights Reserved. Your Collaborative Planning Guide State of Oklahoma April 9,
Confidential and Proprietary Information © 2012 Express Scripts, Inc. All Rights Reserved 1 AGING-RELATED MEDICATIONS: COST AND UTILIZATION PATTERNS Presenter:
 Teva Pharmaceuticals Garrett Hoffman. Agenda  Company Overview  Drivers and Trends  Valuation  Recommendation  WOOF Discusion.
Peterson-Kaiser Health System Tracker What are the recent and forecasted trends in prescription drug spending?
Mental Health and Substance Abuse Prescription Drug Spending Trends: Medicaid and Privately Insured Populations American Public Health Association Annual.
© Copyright 2004 Frost & Sullivan. All Rights Reserved. World Generics and Biogenerics Markets Regulatory and Patent Uncertainties Constrain Development.
Highlights of the 2007 NRMCA Industry Data Survey
Analyzing Financial Statements
Growth in prescription spending had slowed, but increased rapidly in 2014 and 2015
BASICS IN PHARMA.
Medicaid Expansion.
2016 Energy Production and Consumption Declines

The Basics of Pharmacy Benefit Management (PBM)
二零一一年度業績報告 2011 Annual Results March, 2012
South Africa-The Future Of Foodservice To Ken Research.
An Increasing Demand for Prescription Drugs Drives Profitability
Express Scripts Exclusions Target 25 Drug Classes
2006 Healthcare Conference
Growth in prescription spending had slowed, but increased rapidly in 2014 and 2015
Pharmacy – Fully Insured versus Self Funding
State of the pharmacy market
The Rx for Rx Savings Breaking the Status Quo!
Presentation transcript:

2007 Drug Trend Brian Seiz, PharmD Express Scripts

 2008 Express Scripts, Inc. All Rights Reserved. 2 What Does Express Scripts Mean by “Drug Trend”? We report total ingredient cost year over year –Plan design decisions determine cost- sharing We report Express Scripts commercial book of business We track specialty separately

 2008 Express Scripts, Inc. All Rights Reserved. 3 Lowest Drug Trend Since 1994… Note: Specialty tracked separately as of 2003 Drug Trend

 2008 Express Scripts, Inc. All Rights Reserved. 4 Lowest Drug Trend Since 1994… …Record High Generic Fill Rate Note: Specialty tracked separately as of 2003 GFR Drug Trend

 2008 Express Scripts, Inc. All Rights Reserved. Drug Safety Concerns One Lesson From Vioxx: Approach New Drugs With Caution By MARY DUENWALD October 5, 2004 New Avandia study reaffirms heart risk By Rita Rubin, USA TODAY January 16, 2008 FDA reviewing asthma drug, suicide link Bloomberg News / March 28, 2008

 2008 Express Scripts, Inc. All Rights Reserved. 66 Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2008 Express Scripts, Inc. All Rights Reserved. 77 Components of Rx Cost Trend * * Excluding Specialty starting in 2003 Price: The difference in average price per unit of common drugs compared to previous year. Typical drivers include market dynamics and competition.

 2008 Express Scripts, Inc. All Rights Reserved. 88 Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2008 Express Scripts, Inc. All Rights Reserved. 99 Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2008 Express Scripts, Inc. All Rights Reserved. 10 Brand Drug Prices Up Generic Drug Prices Down Brand Price Drivers: Hypnotics: % Dermatologicals: % Contraceptives: % Brand Price Drivers: Hypnotics: % Dermatologicals: % Contraceptives: % Brands: Prices Up 7.4%

 2008 Express Scripts, Inc. All Rights Reserved. 11 Brand Drug Prices Up Generic Drug Prices Down Brands: Prices Up 7.4% Generic Price Drivers: Antihyperlipidemics: % Antidepressants: % Gastrointestinals: % Generic Price Drivers: Antihyperlipidemics: % Antidepressants: % Gastrointestinals: % Generics: Prices down 3.1%

 2008 Express Scripts, Inc. All Rights Reserved. 12 Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2008 Express Scripts, Inc. All Rights Reserved. 13 Components of Rx Cost Trend * * Excluding Specialty starting in 2003 Brand/Generic Mix: Reflects the cost impact of increased or decreased generic use. Typical drivers: new generics and maturation of the therapy class

 2008 Express Scripts, Inc. All Rights Reserved. 14 Top Brand/Generic Mix Changes Ranked by Percent Change

 2008 Express Scripts, Inc. All Rights Reserved. 15 Components of Rx Cost Trend * * Excluding Specialty starting in 2003 Therapeutic Mix: Changes in the cost per Rx due to use of more or less expensive drugs and drug strengths. Typical drivers include new products replacing old products.

 2008 Express Scripts, Inc. All Rights Reserved. Top Therapeutic Mix Changes 16 Januvia ® Combo Products Lyrica ® Lamictal ® Seroquel ® Abilify ® Crestor ® Vytorin ® Prilosec OTC ®

 2008 Express Scripts, Inc. All Rights Reserved. 17 Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2008 Express Scripts, Inc. All Rights Reserved. 18 Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2008 Express Scripts, Inc. All Rights Reserved. 19 Utilization = Prevalence + Intensity Proportion of members utilizing drugs Impacted by diagnosis and therapy plan Prevalence 0.7%

 2008 Express Scripts, Inc. All Rights Reserved. 20 Utilization = Prevalence + Intensity Proportion of members utilizing drugs Impacted by diagnosis and therapy plan Prevalence Number of Rxs filled among utilizers Impacted by length of therapy Intensity 0.7% 1.8%

 2008 Express Scripts, Inc. All Rights Reserved. Impact of Utilization on Trend 21 % Change in Utilization

 2008 Express Scripts, Inc. All Rights Reserved. 22 Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2008 Express Scripts, Inc. All Rights Reserved. 23 Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2008 Express Scripts, Inc. All Rights Reserved. 24 Continued Drop in New Drug Approvals Lowest approval rate since 1983 U.S. Food and Drug Administration Approved New Molecular Entities

 2008 Express Scripts, Inc. All Rights Reserved. 25 Components of Rx Cost Trend * * Excluding Specialty starting in 2003

 2008 Express Scripts, Inc. All Rights Reserved. 26 Females Had a Higher Trend on a Higher Base Trend 5.1% Trend 4.4% PMPY

 2008 Express Scripts, Inc. All Rights Reserved. 27 Children Had a Higher Trend on a Lower Base PMPY Trend 5.5% Trend 6% Trend 3.3% Trend 4%

 2008 Express Scripts, Inc. All Rights Reserved. 28 Top Therapy Classes 2007

 2008 Express Scripts, Inc. All Rights Reserved. 29 Top Therapy Classes 2007

 2008 Express Scripts, Inc. All Rights Reserved. Therapy Class #1: Lipids Generics Drove Down Trend 30 Class Trend: -9.0%

 2008 Express Scripts, Inc. All Rights Reserved. Therapy Class #1: Lipids Generics Drove Down Trend 31 Class Trend: -9.0%

 2008 Express Scripts, Inc. All Rights Reserved. 32 Active Management Drove Down Lipid Trend

 2008 Express Scripts, Inc. All Rights Reserved. Therapy Class #21: Hypnotics Generics Drove Down Trend 33 Class Trend: -7.7%

 2008 Express Scripts, Inc. All Rights Reserved. Therapy Class #21: Hypnotics Generics Drove Down Trend 34 Class Trend: -7.7%

 2008 Express Scripts, Inc. All Rights Reserved. 35 Hypnotic Trend Reversed in 2007

 2008 Express Scripts, Inc. All Rights Reserved. 36 Active Management Drove Down Hypnotic Trend

 2008 Express Scripts, Inc. All Rights Reserved. 37 Member Share of Costs is Stable

 2008 Express Scripts, Inc. All Rights Reserved. 38 Member Share of Costs is Stable

 2008 Express Scripts, Inc. All Rights Reserved. Average Copays

 2008 Express Scripts, Inc. All Rights Reserved. Average Copays

 2008 Express Scripts, Inc. All Rights Reserved. 41 Trend Forecast 5.9% 4.7%

 2008 Express Scripts, Inc. All Rights Reserved. 42 Trend Forecast 5.9% 4.7%

 2008 Express Scripts, Inc. All Rights Reserved. 43 Trend Forecast 5.9% 4.7% 6.1% 8.2% 5.6% 7.2%

 2008 Express Scripts, Inc. All Rights Reserved. 44 Annual Sales $ Billion Imitrex Lamictal Risperdal Fosamax Effexor XR Other Valtrex Topamax Prevacid Other Cozaar/Hyzaar Lipitor Other Levaquin Zyprexa Actos Protonix Other Brand Drugs Going Generic Soon More than $65 billion within the next five years Adderall XR Seroquel Lexapro Plavix Singulair Other Depakote Flomax Diovan/HCT $13.1 Billion $10.3 Billion $13.7 Billion $9.1 Billion $19.6 Billion Other

 2008 Express Scripts, Inc. All Rights Reserved. 45 Generic Opportunities Remain Strong

 2008 Express Scripts, Inc. All Rights Reserved. 46 Generic Opportunities Remain Strong

 2008 Express Scripts, Inc. All Rights Reserved. 47 Drug Trend Highlights Generic Opportunities Safety concerns Drug Trend at its lowest in over 10 years Benefit design Utilization programs Active Management can drive lower trend $65 billion of drug coming off patent Consumer engagement The opportunities continue to grow